Randomized study with cyclosporine in kidney transplantation: 10-year follow-up

被引:0
作者
Ponticelli, C
Civati, G
Tarantino, A
diPalo, FQ
Corbetta, G
Minetti, L
Vegeto, A
Belli, L
机构
[1] OSPED NIGUARDA CA GRANDA, DIV NEFROL, MILAN, ITALY
[2] SANDOZ PRODOTTI FARMACEUT SPA, DIREZ MED, MILAN, ITALY
[3] OSPED MAGGIORE, IRCCS, DIV CHIRURG TRAPLANTI, MILAN, ITALY
[4] OSPED NIGUARDA CA GRANDA, DIV CHIRURG, MILAN, ITALY
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 1996年 / 7卷 / 05期
关键词
long term; graft half-life; prospective study;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
This study presents the 10-yr follow-up results of a multicenter controlled trial on 108 recipients of cadaveric renal transplantation, randomized to receive cyclosporine (N = 55) or azathioprine (N = 53), both in combination with steroids, The 10-yr patient survival rate was 89% in the cyclosporine group and 83% in the azathioprine group (P = not significant (NS)); the 10-yr graft survival was 56% and 35%, respectively (log-rank test, P = 0.009), The half-life of grafts functioning after 1 yr was 15.4 +/- 3.9 versus 10.6 +/- 3.6, P = NS), The rate of early rejection in the cyclosporine group was significantly lower than that in the azathioprine group (0.30 versus 1.4, P < 0.01), Although the mean creatinine clearance rate was always higher in the azathioprine group, the decline in graft function from the first to the tenth yr was not significantly different between the two groups (-13.0 +/- 16.4 versus -12.3 +/- 19 mL/min, P = NS). In cadaveric renal transplantation, cyclosporing allows better graft survival than azathioprine, not only in the short term but also in the long term, with similar attrition of graft function for up to 10 yr.
引用
收藏
页码:792 / 797
页数:6
相关论文
共 38 条
[1]   RISK-FACTORS FOR CHRONIC REJECTION IN RENAL-ALLOGRAFT RECIPIENTS [J].
ALMOND, PS ;
MATAS, A ;
GILLINGHAM, K ;
DUNN, DL ;
PAYNE, WD ;
GORES, P ;
GRUESSNER, R ;
NAJARIAN, JS ;
FERGUSON ;
PAUL ;
SCHAFFER .
TRANSPLANTATION, 1993, 55 (04) :752-757
[2]   CYCLOSPORINE (SANDIMMUN(R)) IN CADAVERIC RENAL-TRANSPLANTATION - 10-YEAR FOLLOW-UP OF A MULTICENTER TRIAL [J].
BEVERIDGE, T ;
CALNE, RY .
TRANSPLANTATION, 1995, 59 (11) :1568-1570
[3]   LONG-TERM EFFICACY AND SAFETY OF CYCLOSPORINE IN RENAL-TRANSPLANT RECIPIENTS [J].
BURKE, JF ;
PIRSCH, JD ;
RAMOS, EL ;
SALOMON, DR ;
STABLEIN, DM ;
VANBUREN, DH ;
WEST, JC .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (06) :358-363
[4]   CYCLOSPORIN-A IN CADAVERIC ORGAN-TRANSPLANTATION [J].
CALNE, RY ;
WHITE, DJG ;
EVANS, DB ;
THIRU, S ;
HENDERSON, RG ;
HAMILTON, DV ;
ROLLES, K ;
MCMASTER, P ;
DUFFY, TJ ;
MACDOUGALL, BRD ;
WILLIAMS, R .
BRITISH MEDICAL JOURNAL, 1981, 282 (6268) :934-936
[5]  
CANAFAX DM, 1990, CLIN TRANSPLANT, V4, P321
[6]  
CECKA JM, 1994, CLIN TRANSPLANT, V8, P324
[7]  
Dieperink H, 1987, Nephrol Dial Transplant, V1, P251
[8]  
EGIDI F, 1985, TRANSPLANT P, V17, P2096
[9]  
FERGUSON R, 1994, CLIN TRANSPLANT, V8, P328
[10]   RISK-FACTORS FOR CYCLOSPORINE-INDUCED NEPHROPATHY IN PATIENTS WITH AUTOIMMUNE-DISEASES [J].
FEUTREN, G ;
MIHATSCH, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (25) :1654-1660